Endorsement complements the company’s ongoing commitment to physician
education
MASON, Ohio--(BUSINESS WIRE)--Feb. 19, 2019--
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatment
for atrial fibrillation (Afib) and left atrial appendage management,
today announced that The Society of Thoracic Surgeons (STS) has endorsed
its Advanced Ablation course for both physicians and fellows. The course
provides surgeons and other medical professionals with a comprehensive
overview of the treatment of Afib during cardiac surgery.
Founded in 1964, STS is a not-for-profit organization representing more
than 7,500 cardiothoracic surgeons, researchers, and allied health care
professionals worldwide who are dedicated to ensuring the best possible
outcomes for surgeries of the heart, lungs, and esophagus, as well as
other procedures within the chest. Its mission is to enhance the ability
of cardiothoracic surgeons to provide the highest quality patient care
through education, research, and advocacy.
“We want to thank the STS for this recent endorsement of our educational
programs,” said Michael Carrel, President and Chief Executive Officer of
AtriCure. “One of the foundational elements of our company is education,
and we have partnered with leading physician faculty around the world to
deliver robust programming. We share a common vision with the STS and
look forward to continuing to train and educate as many physicians as
possible on concomitant surgical Afib treatment.”
Since receiving PMA approval for the Isolator® Synergy™
Ablation System for the treatment of persistent and long-standing
persistent Afib during cardiac surgery in 2011, AtriCure has trained
over 2,300 surgeons, cardiologists, and other allied health
professionals in the United States.
“AtriCure’s receipt of STS’ endorsement is validation of the physician
education curriculum offered by the company,” said Dr. James L. Cox,
Professor of Cardiac Surgery at Northwestern University in Chicago.
“Since I have been involved with AtriCure, I have seen firsthand their
commitment to providing world-class educational courses, which has in
turn led to more physicians treating patients. I’m confident that
continuing these efforts will lead to more and more of my colleagues
seeing the benefits of concomitant Afib surgery, so that no patient gets
left without the opportunity to be treated.”
About AtriCure, Inc.
AtriCure, Inc. provides innovative technologies for the treatment of
Afib and related conditions. Afib affects more than 33 million people
worldwide. Electrophysiologists and cardiothoracic surgeons around the
globe use AtriCure technologies for the treatment of Afib and reduction
of Afib related complications. AtriCure’s Isolator® Synergy™
Ablation System is the first and only medical device to receive FDA
approval for the treatment of persistent Afib. AtriCure’s AtriClip Left
Atrial Appendage (LAA) Exclusion System products are the most widely
sold LAA management devices worldwide, with more than 170,000 implanted
to date. For more information, visit AtriCure.com or follow us on
Twitter @AtriCure.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190219005080/en/
Source: AtriCure, Inc.
Valerie Storch-Willhaus
Media Relations
Senior Director,
Corporate Marketing and Communications
(612) 605-3311
vstorch-willhaus@AtriCure.com
Andy Wade
Investor Relations
Senior Vice President and Chief
Financial Officer
(513) 755-4564
awade@AtriCure.com
